Neurofibromatosis (NF) is a genetic disorder causing skin abnormalities and tumors that form on nerve tissues. These tumors can be small or large and can occur anywhere in the body, including the brain, spinal cord, large nerves, or smaller nerves. NF affects persons of both sexes and all racial groups. There are 2 types of neurofibromatosis, called NF1 and NF2. These are 2 distinct disorders that are caused by mutations (changes) in different genes. NF1 is also referred to as Von Recklinghausen disease and is a rather common genetic disease, affecting approximately 1 in 4000 individuals. Some patients who have NF1 only display characteristic skin abnormalities such as café-au-lait spots , which are flat, hyperpigmented (darker than surrounding skin) areas. Other patients can have severe physical complications such as malignant (cancerous) tumors or have mental retardation. The July 16, 2008, issue of JAMA includes an article about the learning deficits associated with NF. Learning disability is the most frequent complication in children with NF1.
NF2 is much more rare than NF1, affecting less than 1 in 30 000 individuals, usually becoming apparent in the late teens, and typically causing hearing loss and problems with balance due to tumors on nerves to the ears.
Grahic Jump Location
Café-au-lait spots are already visible at or shortly after birth.
Freckling in skin folds, for instance the armpit or inguinal region
Neurofibromas—soft bumps on or under the skin that are tumors arising on or along nerves
Weakness, numbness, tingling, or other symptoms may be present if the NF tumors compress the spinal cord or large peripheral nerves.
Visual difficulties in children can indicate a tumor of the visual pathway.
Bone deformities, including a bowed lower leg or scoliosis (curved spine)
Learning disability and mental retardation are commonly associated with NF1.
About 50% of NF patients have an affected parent, but in 50% the mutation occurs spontaneously in a family with no previous history of NF. The diagnosis of NF1 and NF2 is based on clinical symptoms. The NF1 diagnosis can usually be made before the age of 6, whereas the symptoms of NF2 often only arise in the late teens. Since the 2 genes that cause NF1 and NF2 have been discovered, genetic testing is also available.
Because of the wide range of symptoms and complications that can arise in NF1 and NF2, patients should be monitored by a team of specialists. There is currently no cure for NF1 or NF2. Surgical treatment is aimed at alleviating the symptoms that arise when NF tumors compress nearby bodily tissues and can cause damage to those tissues or organs. Chemotherapy (anticancer drugs) may also be offered when the tumors associated with NF are malignant. This occurs in less than 10% of persons who have NF.
National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov
American Academy of Pediatrics http://www.aap.org
Neurofibromatosis Inc http://www.nfinc.org
The Children's Tumor Foundation http://www.ctf.org
To find this and previous JAMA Patient Pages, go to the Patient Page Index on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish. A Patient Page on the basics of genetics was published in the March 19, 2008, issue.
Sources: National Institute of Neurological Disorders and Stroke, National Human Genome Research Institute, American Academy of Pediatrics, Neurofibromatosis Inc
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.
TOPIC: NEUROLOGICAL DISORDERS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.